175 related articles for article (PubMed ID: 3080261)
1. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
Williams DO; Borer J; Braunwald E; Chesebro JH; Cohen LS; Dalen J; Dodge HT; Francis CK; Knatterud G; Ludbrook P
Circulation; 1986 Feb; 73(2):338-46. PubMed ID: 3080261
[TBL] [Abstract][Full Text] [Related]
2. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
3. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
4. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
Gold HK; Leinbach RC; Garabedian HD; Yasuda T; Johns JA; Grossbard EB; Palacios I; Collen D
Circulation; 1986 Feb; 73(2):347-52. PubMed ID: 3080262
[TBL] [Abstract][Full Text] [Related]
5. [Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction].
Gao R
Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Aug; 19(4):228-30, 267-8. PubMed ID: 1813288
[TBL] [Abstract][Full Text] [Related]
6. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
7. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
[TBL] [Abstract][Full Text] [Related]
8. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Magnani B
J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration.
McKendall GR; Attubato MJ; Drew TM; Feit F; Sharaf BL; Thomas ES; Teichman S; McDonald MJ; Williams DO
J Am Coll Cardiol; 1991 Dec; 18(7):1774-8. PubMed ID: 1960329
[TBL] [Abstract][Full Text] [Related]
11. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
12. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
Chesebro JH; Knatterud G; Roberts R; Borer J; Cohen LS; Dalen J; Dodge HT; Francis CK; Hillis D; Ludbrook P
Circulation; 1987 Jul; 76(1):142-54. PubMed ID: 3109764
[TBL] [Abstract][Full Text] [Related]
13. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
14. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
Kalbfleisch J; Thadani U; LittleJohn JK; Brown G; Magorien R; Kutcher M; Taylor G; Maddox WT; Campbell WB; Perry J
Am J Cardiol; 1992 May; 69(14):1120-7. PubMed ID: 1575179
[TBL] [Abstract][Full Text] [Related]
16. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
17. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
[TBL] [Abstract][Full Text] [Related]
18. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
Jpn Circ J; 1991 Mar; 55(3):250-61. PubMed ID: 1903167
[TBL] [Abstract][Full Text] [Related]
19. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
[TBL] [Abstract][Full Text] [Related]
20. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]